https://www.selleckchem.com/products/favipiravir-t-705.html Despite the significant therapeutic advances in T-cell immunotherapy, many malignancies remain unresponsive, which might be because of the negative regulation of T cells by the tumor microenvironment (TME). T cells discriminate tumor cells and normal cells through T-cell receptors (TCRs); therefore, we generated a novel type of TCR-drug conjugates (TDCs) by referring antibody-drug conjugations (ADCs) to overcome the effects of the TME on T cells while preserving the specificity of TCR for tumor recognition. We selected HLA-A2/NY-ESO-1157-165 (peptide NY-ESO-1157-165 in complex with human leukocyte antigen serotype HLA-A*0201) as the antigen and the antigen-specific TCR (1G4113) as the carrier. By sortase A-mediated ligation, we obtained three NY-TCR-vcMMAEs and further studied their properties, antitumor activity, and toxicity in vitro and in vivo. We found that all the NY-TCR-vcMMAEs had high endocytosis efficiency and specifically killed HLA-A2/NY-ESO-1157-165 positive tumor cells. In xenograft models, one of the TDCs, NY-TCR-2M, was effectively and specifically distributed into tumor tissues and inhibited tumor growth without inducing obvious toxicity. Our results demonstrated that TCRs can be carriers of toxic payloads and that the TDCs thus formed can specifically inhibit tumor growth, neglecting the immune microenvironment.A paper-based method for heating preconcentration (PAD-HP) has been developed for the determination of Pb2+, Cd2+, Fe3+, and Ni2+. The design of our heating system was evaluated for dual quantification of ions using electrochemical and colorimetric methods simultaneously. The PAD-HP was used to detect Pb2+ and Cd2+ by anodic stripping voltammetry and to detect Fe3+ and Ni2+ by colorimetric reactions. Assay conditions were optimized by evaluating performance when changing the concentration of the colorimetric reagent, eluent volume, electrolyte concentration, and electrochemical para